Atossa Genetics Announces FDA Approval of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient
SEATTLE, Dec. 03, 2018 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and […]